Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PROCEPT BioRobotics Corporation - Common Stock (NQ:PRCT)

54.78 -2.96 (-5.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PROCEPT BioRobotics Corporation - Common Stock

< Previous 1 2 3 4 5 Next >
WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation
Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a... 
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada
From PROCEPT BioRobotics
Via GlobeNewswire
4 Analysts Assess PROCEPT BioRobotics: What You Need To Know
Via Benzinga
Earnings Scheduled For February 25, 2025
Via Benzinga
How Is The Market Feeling About PROCEPT BioRobotics?
Via Benzinga
5 Analysts Assess PROCEPT BioRobotics: What You Need To Know
Via Benzinga
Looking Into PROCEPT BioRobotics's Recent Short Interest
Via Benzinga
PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® to Report Fourth Quarter 2024 Financial Results on February 25, 2025 and Attend the TD Cowen 45th Annual Healthcare Conference and the 2025 Leerink Partners Healthcare Conference
From PROCEPT BioRobotics
Via GlobeNewswire
Spruce Point Sees Trouble Ahead For Procept BioRobotics
Spruce Point Capital warns of Procept BioRobotics' overstated market potential and growth claims, citing niche product limitations and valuation risks. 
Via Benzinga
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
The Analyst Landscape: 6 Takes On PROCEPT BioRobotics
Via Benzinga
PROCEPT BioRobotics's Earnings Outlook
Via Benzinga
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%). 
Via Benzinga
PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock
From PROCEPT BioRobotics
Via GlobeNewswire
What Analysts Are Saying About PROCEPT BioRobotics Stock
Via Benzinga
Royal Caribbean Sails Onto The IBD 50: Build Your List Of Stocks To Watch With These Top IBD Screens
Royal Caribbean earns its spot on the Big Cap 20 with a best-possible 99 Composite Rating, putting it in the top 1% of all stocks. 
Via Investor's Business Daily
PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock
From PROCEPT BioRobotics
Via GlobeNewswire
Surgical Robotics Provider PROCEPT BioRobotics' Q3 Earnings Beats Street View, Analyst Optimistic About Upside Potential
PROCEPT BioRobotics stock gains as Q3 earnings beat estimates with revenue up 66% YoY, driven by strong system sales and consumable revenue growth. 
Via Benzinga
Topics Earnings
Exposures Financial
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
Navigating 6 Analyst Ratings For PROCEPT BioRobotics
Via Benzinga
Procept Biorobotics, A Top 5% Stock, Makes A Bullish Move On Quarterly Beat And Raise
The company sells systems that perform aquablation to treat enlarged prostates. 
Via Investor's Business Daily
PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer
From PROCEPT BioRobotics
Via GlobeNewswire
Jim Cramer Says This Retailer Yields 3%: 'Which Is Quite Good'
Jim Cramer discusses PROCEPT BioRobotics, Zoetis, Target and Consolidated Edison. " 
Via Benzinga
PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
Lucid, Grifols And Amer Sports Are Among Top 8 Mid Cap Stock Gainers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.